CAR-T therapy in solid tumors
Cancer Cell · 2025-04 · 43 (4) · 665-679
DOI: 10.1016/j.ccell.2025.03.019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2025-04. Verfasst von Bing Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit wurde bisher 289-mal zitiert (Crossref) und nennt 140 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission, Science and Technology Innovation Plan Of Shanghai Science and Technology Commission, Shanghai Rising-Star Program.
Abstract (Originalsprache)
While chimeric antigen receptor (CAR) T cell therapy has shown great success in hematologic malignancies, the effectiveness in solid tumors has been limited by several factors, including antigenic heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). In this review, we discuss the advancements made in clinical studies and challenges faced by CAR-T therapy for solid tumors. To enhance CAR-T cell efficacy in solid tumors, we explore strategies such as enhancing T cell persistence and cytotoxicity, targeting multiple antigens, and utilizing innovative allogeneic CAR-T cell manufacturing. Additionally, we highlight the potential benefits of combining CAR-T therapies with immune checkpoint inhibitors and other treatment modalities to overcome TME limitations. We remain optimistic about the future of CAR-T cell therapy in solid tumors, emphasizing the need for continued research to refine therapeutic approaches and address the clinical needs of patients with cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 2…
Förderung
- Shanghai Municipal Health Commission
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- Shanghai Rising-Star Program
- Program of Shanghai Academic Research Leader
- National Key Research and Development Program of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M. (2025). CAR-T therapy in solid tumors. Cancer Cell, 43(4), 665-679. https://doi.org/10.1016/j.ccell.2025.03.019
Vancouver
Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43(4):665-679. doi:10.1016/j.ccell.2025.03.019
BibTeX
@article{Du2025,
author = {Du, Bing and Qin, Juliang and Lin, Boxu and Zhang, Jiqin and Li, Dali and Liu, Mingyao},
title = {CAR-T therapy in solid tumors},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {4},
pages = {665--679},
doi = {10.1016/j.ccell.2025.03.019}
}
EUVIMED